Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| ADA | Anti-drug antibody |
| AHFS | American Hospital Formulary Service |
| ANB019 | Development code for imsidolimab |
| BLA | Biologics License Application |
| BSA | Body surface area |
| CGI | Clinical Global Impression |
| CI | Confidence interval |
| DLQI | Dermatology Life Quality Index |
| EMA | European Medicines Agency |
| EQ-5D | EuroQol five-dimension questionnaire |
| ERASPEN | European Rare and Severe Psoriasis Expert Network |
| FDA | U.S. Food and Drug Administration |
| GMA | Granulocyte and monocyte adsorption apheresis |
| GPP | Generalized pustular psoriasis |
| GPPASI | Generalized Pustular Psoriasis Area and Severity Index |
| GPPGA | Generalized Pustular Psoriasis Physician Global Assessment |
| GPPPGA | Generalized Pustular Psoriasis Physician Global Assessment |
| HCRU | Healthcare resource utilization |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| IgG4 | Immunoglobulin G4 |
| IL | Interleukin |
| IL36RN | Interleukin 36 receptor antagonist gene |
| IV | Intravenous |
| LOT | Line of therapy |
| MHLW | Ministry of Health, Labour and Welfare |
| NICE | National Institute for Health and Care Excellence |
| PBO | Placebo |
| PDUFA | Prescription Drug User Fee Act |
| PPPM | Per patient per month |
| PRS | Pustulation Rating Scale |
| PsO | Psoriasis |
| PV | Psoriasis vulgaris |
| QoL | Quality of life |
| SAE | Serious adverse event |
| SAP | Statistical analysis plan |
| SC | Subcutaneous |
| SD | Standard deviation |
| TEAE | Treatment-emergent adverse event |
| TNF | Tumor necrosis factor |